Abeona Therapeutics Receives Guidance From FDA
July 18, 2017
Abeona Therapeutics receives guidance from the FDA; recommends accelerating the EB-101 program for patients with epidermolysis bullosa into a pivotal Phase 3 trial.
Read More >Abeona Therapeutics receives guidance from the FDA; recommends accelerating the EB-101 program for patients with epidermolysis bullosa into a pivotal Phase 3 trial.
Read More >